The study explores the association between immune system features and the therapeutic activity of everolimus in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (mBC). The researchers aimed to identify potential biomarkers that could predict the response to everolimus-based treatment.
The study retrospectively analyzed three different cohorts of HR+ mBC patients who were treated with everolimus-based regimens. The analysis included various parameters such as tumor-associated immune pathways, neutrophil-to-lymphocyte ratio (NLR), circulating lymphocytes, and endothelial cells (CECs).
The findings of the study revealed that certain immune system features were associated with response to everolimus treatment. Responders showed higher levels of specific lymphocyte subpopulations (CD3+/CD8+, CD3+/CD4+, and overall T lymphocytes) compared to non-responders. Additionally, responders exhibited reduced levels of CECs, a marker of tumor neoangiogenesis, after treatment. Patients with a low NLR also had better progression-free survival.
These results suggest that lymphocyte subpopulations, CECs, and NLR could potentially serve as biomarkers to predict the response to everolimus-based regimens in HR+ mBC. If validated in further studies, these biomarkers could be useful in clinical practice for selecting and monitoring patients undergoing everolimus-based treatment.
Overall, this exploratory study provides valuable insights into the potential surrogate biomarkers of response to everolimus-based treatment in HR+ breast cancer. Further research is needed to confirm and expand upon these findings, but they offer promising prospects for personalized treatment approaches in the future.
The study retrospectively analyzed three different cohorts of HR+ mBC patients who were treated with everolimus-based regimens. The analysis included various parameters such as tumor-associated immune pathways, neutrophil-to-lymphocyte ratio (NLR), circulating lymphocytes, and endothelial cells (CECs).
The findings of the study revealed that certain immune system features were associated with response to everolimus treatment. Responders showed higher levels of specific lymphocyte subpopulations (CD3+/CD8+, CD3+/CD4+, and overall T lymphocytes) compared to non-responders. Additionally, responders exhibited reduced levels of CECs, a marker of tumor neoangiogenesis, after treatment. Patients with a low NLR also had better progression-free survival.
These results suggest that lymphocyte subpopulations, CECs, and NLR could potentially serve as biomarkers to predict the response to everolimus-based regimens in HR+ mBC. If validated in further studies, these biomarkers could be useful in clinical practice for selecting and monitoring patients undergoing everolimus-based treatment.
Overall, this exploratory study provides valuable insights into the potential surrogate biomarkers of response to everolimus-based treatment in HR+ breast cancer. Further research is needed to confirm and expand upon these findings, but they offer promising prospects for personalized treatment approaches in the future.